bronchitis%20-%20chronic%20in%20acute%20exacerbation
BRONCHITIS - CHRONIC IN ACUTE EXACERBATION

Chronic bronchitis is an infection of the trachea and bronchi for at least 3 consecutive months for more than 2 consecutive years.
The patient experiences symptoms of increase in dyspnea, sputum volume and sputum purulence over baseline on most days.

Diagnosis is basically based on clinical presentation.

Supportive Therapy

Supportive Therapy

Hydration

  • Maintain adequate hydration to prevent excessive mucus viscosity

Nutritional Programs

  • There are no direct or measurable effects on lung function in treating malnutrition but subjective relief & objective improvement in strength & exercise performance do occur
    • Dietary supplementation should be considered if patient is malnourished (body weight <85% of ideal) or experiencing early satiety
  • Advise patient to obtain nutritional counseling to reduce weight if obese

Oxygen Therapy

  • Cornerstone of COPD exacerbation treatment
  • Low-flow O2 should be administered if hypoxemia is present
  • Excess use of O2 should be avoided as this may lead to progressive hypercapnia, either by decreasing hypoxic ventilatory drive or by worsening ventilation-perfusion mismatching within the lung
  • Once O2 therapy is initiated, arterial blood gas should be monitored 30-60 minutes later to ensure satisfactory oxygenation without acidosis or CO2 retention
  • Goal of supplemental O2 therapy should be arterial blood gas at or just above 60 mmHg

Noninvasive Positive Pressure Ventilation

  • Frequently used for inpatient management of AECB patients who are significantly hypoxemic or with a serum pH <7.3
  • Improves ventilation and lower pCO2 levels and may be a means of avoiding intubation
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 25 Oct 2016

Nivolumab did not meet the primary endpoint of superior progression-free survival (PFS) vs platinum-based chemotherapy in the phase III Checkmate026 trial in patients with stage IV recurrent, PD-L1–positive non-small-cell lung carcinoma (NSCLC), according to results reported recently at the European Society of Medical Oncology (ESMO) Congress 2016. 

Pearl Toh, 24 Nov 2016
New treatments such as pirfenidone and nintedanib slow lung function decline and progression of idiopathic pulmonary fibrosis (IPF), although response to treatment can vary dramatically among patients, according to a presentation at the 21st Congress of the Asian Pacific Society of Respirology (APSR 2016) held in Bangkok, Thailand.
16 Oct 2016
Irritable bowel syndrome and asthma share a bidirectional association, a new study reports. Further, atopy potentially plays a role in the underlying mechanisms of this association.
Audrey Abella, 09 May 2018
The potent and highly selective RET* inhibitor BLU-667 was well-tolerated and exhibited promising clinical activity among patients with advanced, RET-altered solid cancers that progressed despite multikinase inhibitor therapy, according to data presented at AACR 2018.